Trial Profile
Effect of rosiglitazone maleate (Avandia) on carotid intima media thickness, brachial artery reactivity, glucose metabolism, blood lipid concentrations, body fat distribution, and biochemical markers of cardiovascular risk in patients with the HIV metabolic syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Metabolic syndrome
- Focus Biomarker; Pharmacodynamics
- 15 Dec 2009 Actual end date (1 Dec 2009) added as reported by ClinicalTrials.gov
- 15 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 24 Sep 2008 Planned end date addes as 1 Dec 2010 as reported by ClinicalTrials.gov.